Complementary effect of Roe's congenital heart disease treatment compared to Wade's

Published Date: 16 Feb 2023

As more states repeal or restrict abortion laws, the number of patients, the number of workers needed, and the cost of heart disease will increase. How should hospitals and policy makers prepare?

Read Full News

Latest News

How Donors Died May Not Matter for Heart Transplant Outcomes

Recipients of heart transplants have similar 10-year survival and graft health outcomes, regardless of whether hearts are obtained from donors after circulatory death or brain death, a study finds.

Are Medical Schools Doing Enough to Teach Clinical AI?

As new clinical AI tools proliferate, students are growing worried about the burden of keeping up. Are medical schools doing enough to train them?

A Common Phone Metric May Be Brain Health’s Next Frontier

New research linking heart rate variability to glymphatic clearance could lead to a simple new biomarker of dementia risk.

Why Primary Hyperaldosteronism Remains Underdiagnosed

Primary hyperaldosteronism may account for a sizable share of resistant hypertension, yet experts say most cases still go undiagnosed despite clear treatment options.

HFpEF Diagnosis Enters a New Era

New imaging tools, exercise testing, and phenotype-based therapy are reshaping how clinicians diagnose and treat HFpEF.

Sleepy Days and Restless Nights Linked to Hypertension Risk

Adults who report excessive daytime sleepiness and difficulty falling asleep face more than triple the risk of developing hypertension.

Todays Updates

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Todays Updates

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Latest News

Recipients of heart transplants have similar 10-year survival and graft health outcomes, regardless of whether hearts are obtained from donors after circulatory death or brain death, a study finds.

As new clinical AI tools proliferate, students are growing worried about the burden of keeping up. Are medical schools doing enough to train them?

New research linking heart rate variability to glymphatic clearance could lead to a simple new biomarker of dementia risk.

Primary hyperaldosteronism may account for a sizable share of resistant hypertension, yet experts say most cases still go undiagnosed despite clear treatment options.

New imaging tools, exercise testing, and phenotype-based therapy are reshaping how clinicians diagnose and treat HFpEF.

Adults who report excessive daytime sleepiness and difficulty falling asleep face more than triple the risk of developing hypertension.

News All Time

Metyrapone Reduces BP in Mild Autonomous Cortisol Secretion

Evening metyrapone treatment reduces blood pressure at the supine position and epicardial fat in patients with mild autonomous cortisol secretion.

New Atrial Fibrillation May Speed Kidney Decline in Adults

In working-age adults, new-onset atrial fibrillation is linked to a faster decline in kidney function and a substantially higher risk of experiencing a 30% or greater reduction in kidney function.

Ultraprocessed Foods: A Factor in Male Fertility Decline?

Emerging evidence links heavily processed dietary patterns to poor semen quality and hormonal changes that may influence reproductive health.

Glycemic Benefits of Testosterone Therapy Wane After 2 Years

A follow-up of the T4DM trial in men with prediabetes or recent-onset type 2 diabetes show no further glycemic improvement after 2 years without ongoing lifestyle modification.

Gene Therapy Appears to Be Safe in FA Cardiomyopathy

Intravenous gene therapy delivering the frataxin gene appears safe and is associated with preliminary signs of reduced heart damage in patients with Friedreich ataxia cardiomyopathy.

Surgery May Extend Survival in EGFR-Mutated Lung Cancer

Surgical removal of residual tumour during TKI therapy may improve survival in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.

AI's 'Blind Trust' Problem Puts Patients at Risk

Panelists at HLTH Europe 2026 warned that clinicians and patients are increasingly deferring to algorithmic outputs over independent judgment.

Protein and Creatine Supplements Are No Longer Niche

The fitness supplements have gone mainstream. How much is too much? How should GLP-1 patients use them? Will creatine save our brains? Here’s what the science says.

Closing the Women's Health Gap With AI and Better Data

From cardiac misdiagnosis to an 8-year wait for endometriosis, experts at HLTH Europe lay out how AI and multimodal data can start closing the gender health gap.

GLP-1s Tied to Higher Risk for Dizziness, Fainting for Some

Hypotension-related events increased after starting GLP-1s in patients taking multiple antihypertensive medications.

Phase 3 HCM Drug Offers Promising Results in Exercise Tests

Treatment with aficamten may improve multiple measures of exercise in patients with obstructive hypertrophic cardiomyopathy, a study finds.

Will Genomics Move From Innovation to Routine Care?

Pharmacogenomics and polygenic risk scores could replace trial-and-error prescribing — but workflow, trust, and equity stand in the way.

How Extreme Heat Threatens Athlete Safety

High temperatures, humidity, and prolonged exertion can overwhelm the body’s cooling systems. Here’s what clinicians should know about heat risk in sport.

GLP-1 Therapy: Can a Myostatin Antibody Preserve Muscle?

A phase 2 trial suggests myostatin inhibition may reduce lean body mass loss during tirzepatide treatment while maintaining overall weight reduction.

Early Pregnancy Thyroid Issues Signal Later Hypothyroidism

Thyroid abnormalities in early pregnancy are associated with an increased risk of developing hypothyroidism later in life.

Shorter Romosozumab Course Works as Well as 12-Month Regimen

A 3-month course of romosozumab followed by denosumab produced bone density gains comparable to those of the standard 12-month regimen in postmenopausal women at high fracture risk.